RESUMEN

INTRODUCTION: The quantification of circulating Epstein-Barr virus (EBV) DNA is used to monitor transplant patients as an early marker of Post-Transplant Lymphoproliferative Disorders (PTLD). So far no standardized methodology exists for such determination. OBJECTIVE: Our purpose was to develop and validate a real-time PCR assay to quantify EBV DNA in clinical samples from transplant recipients. METHODS: A duplex real-time PCR method was developed to amplify DNA from EBV and from a human gene. The EBV load was determined in peripheral blood mononuclear cells (PBMC), plasma and oropharyngeal tissue from 64 non-transplanted patients with lymphoid-hypertrophy (Non-Tx), 47 transplant recipients without PTLD (Tx), 54 recipients with PTLD (Tx-PTLD), and 66 blood donors (BD). WinPEPI, version 11.14 software was used for statistical analysis. RESULTS: Analytical validation: the intra and inter-assays variation coefficients were less than 4.5% (EBV-reaction) and 3% (glyceraldehyde 3-phosphate dehydrogenase - GAPDH reaction). Linear ranges comprised 107-10 EBV genome equivalents (gEq) (EBV-reaction) and 500,000-32 human gEq (GAPDH-reaction). The detection limit was 2.9 EBV gEq (EBV-reaction). Both reactions showed specificity. Application to clinical samples: higher levels of EBV were found in oropharyngeal tissue from transplanted groups with and without PTLD, compared to Non-Tx (p < 0.05). The EBV load in PBMC from the groups of BD, Non-Tx, Tx and Tx-PTLD exhibited increasing levels (p < 0.05). In BD, PBMC and plasma, EBV loads were undetectable. CONCLUSIONS: The performance of the assay was suitable for the required clinical application. The assay may be useful to monitor EBV infection in transplant patients, in particular in laboratories from low-income regions that cannot afford to use commercial assays. .

Asunto(s)

Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Adulto Joven , ADN Viral/sangre , Infecciones por Virus de Epstein-Barr/diagnóstico , Trasplante de Corazón/efectos adversos , /genética , Trasplante de Riñón/efectos adversos , Trasplante de Hígado/efectos adversos , Trastornos Linfoproliferativos/diagnóstico , Trastornos Linfoproliferativos/virología , Reacción en Cadena en Tiempo Real de la Polimerasa , Sensibilidad y Especificidad , Carga Viral

RESUMEN

INTRODUCTION: The quantification of circulating Epstein-Barr virus (EBV) DNA is used to monitor transplant patients as an early marker of Post-Transplant Lymphoproliferative Disorders (PTLD). So far no standardized methodology exists for such determination. OBJECTIVE: Our purpose was to develop and validate a real-time PCR assay to quantify EBV DNA in clinical samples from transplant recipients. METHODS: A duplex real-time PCR method was developed to amplify DNA from EBV and from a human gene. The EBV load was determined in peripheral blood mononuclear cells (PBMC), plasma and oropharyngeal tissue from 64 non-transplanted patients with lymphoid-hypertrophy (Non-Tx), 47 transplant recipients without PTLD (Tx), 54 recipients with PTLD (Tx-PTLD), and 66 blood donors (BD). WinPEPI, version 11.14 software was used for statistical analysis. RESULTS: Analytical validation: the intra and inter-assays variation coefficients were less than 4.5% (EBV-reaction) and 3% (glyceraldehyde 3-phosphate dehydrogenase - GAPDH reaction). Linear ranges comprised 10(7)-10 EBV genome equivalents (gEq) (EBV-reaction) and 500,000-32 human gEq (GAPDH-reaction). The detection limit was 2.9 EBV gEq (EBV-reaction). Both reactions showed specificity. Application to clinical samples: higher levels of EBV were found in oropharyngeal tissue from transplanted groups with and without PTLD, compared to Non-Tx (p<0.05). The EBV load in PBMC from the groups of BD, Non-Tx, Tx and Tx-PTLD exhibited increasing levels (p<0.05). In BD, PBMC and plasma, EBV loads were undetectable. CONCLUSIONS: The performance of the assay was suitable for the required clinical application. The assay may be useful to monitor EBV infection in transplant patients, in particular in laboratories from low-income regions that cannot afford to use commercial assays.

Asunto(s)

ADN Viral/sangre , Infecciones por Virus de Epstein-Barr/diagnóstico , Trasplante de Corazón/efectos adversos , Herpesvirus Humano 4/genética , Trasplante de Riñón/efectos adversos , Trasplante de Hígado/efectos adversos , Trastornos Linfoproliferativos/diagnóstico , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Trastornos Linfoproliferativos/virología , Masculino , Persona de Mediana Edad , Reacción en Cadena en Tiempo Real de la Polimerasa , Sensibilidad y Especificidad , Carga Viral , Adulto Joven

RESUMEN

While worldwide pandemic influenza A(H1N1) pdm case fatality rate (CFR) was 0.4%, Argentina's was 4.5%. A total of 34 strains from mild and severe cases were analyzed. A full genome sequencing was carried out on 26 of these, and a partial sequencing on the remaining eight. We observed no evidence that the high CFR can be attributed to direct virus changes. No evidence of re-assortment, mutations associated with resistance to antiviral drugs, or genetic drift that might contribute to virulence was observed. Although the mutation D225G associated with severity in the latest reports from the Ukraine and Norway is not observed among the Argentine strains, an amino acid change in the area (S206T) surrounding the HA receptor binding domain was observed, the same previously established worldwide.

Asunto(s)

ADN Viral/genética , Subtipo H1N1 del Virus de la Influenza A/genética , Gripe Humana/virología , Mutación/genética , Adolescente , Adulto , Argentina/epidemiología , Niño , Preescolar , Análisis por Conglomerados , Femenino , Humanos , Lactante , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/mortalidad , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , ARN Viral/genética , Receptores Virales/genética , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad , Adulto Joven

RESUMEN

While worldwide pandemic influenza A(H1N1) pdm case fatality rate (CFR) was 0.4%, Argentina's was 4.5%. A total of 34 strains from mild and severe cases were analyzed. A full genome sequencing was carried out on 26 of these, and a partial sequencing on the remaining eight. We observed no evidence that the high CFR can be attributed to direct virus changes. No evidence of re-assortment, mutations associated with resistance to antiviral drugs, or genetic drift that might contribute to virulence was observed. Although the mutation D225G associated with severity in the latest reports from the Ukraine and Norway is not observed among the Argentine strains, an amino acid change in the area (S206T) surrounding the HA receptor binding domain was observed, the same previously established worldwide.

---

Mientras que la tasa de letalidad (CFR) para (H1N1)pdm en todo el mundo era del 0.4%, en la Argentina la mortalidad observada fue de 4.5%. La secuenciación del genoma completo de 26 cepas de virus argentinos de influenza A (H1N1)pdm de casos leves y graves y de 8 cepas secuenciadas parcialmente no mostró evidencia de que la elevada tasa de letalidad se pueda atribuir directamente a cambios en el virus. No se encontraron hallazgos de recombinación, de mutaciones asociadas con la resistencia a los medicamentos antivirales ni de variaciones genéticas que puedan contribuir a la virulencia observada. Si bien la mutación D225G asociada con la gravedad, comunicada en informes procedentes de Ucrania y Noruega, no se ha encontrado en las cepas argentinas estudiadas, se ha observado un cambio aminoacídico en la región (S206T) en torno al dominio del sitio de unión al receptor en la HA, el mismo hallado en cepas distribuidas alrededor del mundo.

Asunto(s)

Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Adulto Joven , ADN Viral/genética , Subtipo H1N1 del Virus de la Influenza A/genética , Gripe Humana/virología , Mutación/genética , Argentina/epidemiología , Análisis por Conglomerados , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/mortalidad , Datos de Secuencia Molecular , Reproducibilidad de los Resultados , ARN Viral/genética , Receptores Virales/genética , Índice de Severidad de la Enfermedad

RESUMEN

UNLABELLED: Two Epstein Barr virus (EBV) genotypes: EBV-1 and EBV-2 have been described. A 30-bp deletion in latent membrane protein-1 gene (del-LMP-1) has been identified in various pathologies. The aim of this study was to determine EBV genotypes and 30-bp deletion frequency in HIV-infected patients from Argentina. The study was performed on 258 individuals: CASES: 144 HIV-infected patients that included: (a) 7 AIDS patients with primary central nervous system lymphoma (PCNSL), (b) 62 AIDS patients, and (c) 75 asymptomatic HIV-infected patients. CONTROLS: 114 HIV-negative individuals. EBV genotypes and variants in LMP-1 gene were detected by polymerase chain reaction (PCR)-Southern blot on DNA extracted from peripheral blood mononuclear cells and brain biopsies. In PCNSL, the presence of EBV was confirmed by EBER RNA in situ hybridization, and DNA sequencing of 3' end LMP-l gene of PCR products was performed. In HIV-infected patients, EBV-1 was detected in 48.6%, EBV-2 in 18.8%, and co-infection with both genotypes in 32.6%. In control group, EBV-1 was present in 74.3%, EBV-2 in 12.4%, and co-infection in 13.3%. Del-LMP-1 was found in 44.4% of HIV-infected patients samples (20.7% alone and 23.7% co-infection with non-deleted form) while it was found in 25.3% (6.3% alone and 19% with co-infection) in HIV-negative individuals. In HIV-infected patients EBV-2, co-infection and 30-bp deletion are more prevalent than in control group. In all, PCNSL brain biopsies samples, del-LMP-1 always was detected with EBV-2, but more cases would have to be included to draw definitive conclusions.

Asunto(s)

Infecciones por Virus de Epstein-Barr/complicaciones , Infecciones por Virus de Epstein-Barr/virología , Infecciones por VIH/complicaciones , VIH , Herpesvirus Humano 4/genética , Proteínas de la Matriz Viral/genética , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Adolescente , Adulto , Argentina , Secuencia de Bases , Biopsia , Southern Blotting , Encéfalo/patología , Encéfalo/virología , Neoplasias del Sistema Nervioso Central/complicaciones , Neoplasias del Sistema Nervioso Central/patología , Variación Genética , Humanos , Leucocitos Mononucleares/virología , Linfoma Relacionado con SIDA/complicaciones , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Eliminación de Secuencia , Especificidad de la Especie

RESUMEN

Hay evidencias que sustentan la opinión de que los HPV de "alto riesgo" tienen una participación determinante en el cáncer de cérvix. Aún es tema de debate el papel de los HPV en la oncogénesis bucal, porque las tasas de detección son menores que en la patología de cuello de útero. Para verificar una posible correlación clinicopatológica de lesiones sospechosas de estar infectadas por HPV, e intentar relacionar la capacidad carcinogénica de los tipos de "alto riesgo" , se estudiaron histológica y virológicamente 35 pacientes con lesiones verrugosas, brillantes y húmedas, vegetaciones y queratosis, ubicadas en mucosa yugal, paladar duro y blando, cara dorsal, ventral y bordes de lengua, encía y rebordes alveolares. En el 32,5% de las muestras, se detectó ADN de HPV, y el tipo 11, solo o combinado con el tipo 16, fue identificado en la mayoría de las lesiones precancerosas y cáncer. Por otro lado, el tipo 16, considerado de alto riesgo, fue identificado en lesiones no relacionadas con una evolución carcinomatosa, como el condiloma acuminado, lesión de aspecto vegetante semejante en algunos casos a una cresta de gallo, localizada tanto en la región anogenital como en boca, y el nevo blanco esponja, enfermedad hereditaria que se manifiesta con lesiones blancas, plegadas y esponjosas que pueden afectar a varios miembros de una familia, con una evolución totalmente benigna.

Asunto(s)

Papillomaviridae , Lesiones Precancerosas , Mucosa Bucal , Neoplasias de la Boca